The company sees increased traction in its core segment of studies of evaluating the generic versions of proprietary drugs that go off patent, as well bright prospects from clinical trials of biosimilars and novel drugs.Veeda Clinical Research filing for Rs 500 crore - Rs 700 crore IPO, sources say
The company sees increased traction in its core segment of studies of evaluating the generic versions of proprietary drugs that go off patent, as well bright prospects from clinical trials of biosimilars and novel drugs.
Subscribe to:
Post Comments (Atom)
-
The company did not export units last month while it had dispatched 804 Etios units in in June 2019.
-
The BRLLR linked to RBI Repo Rate is revised downwards in line with the reduction on Reserve Bank of India Repo Rate from 5.15 percent to 4...
-
Google has tried for years to get Samsung, the world#39;s leading mobile device maker by units sold, to drop its own services and give grea...
No comments:
Post a Comment